RxDoctor Payments Data

Sara Shahid Salles, DO

Spinal Cord Injury Medicine · Lexington, KYNPI 1578599155

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 170 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Hollister Incorporated$124
  • Vertos Medical, Inc.$92
  • Amneal Pharmaceuticals LLC$84
  • Ipsen Biopharmaceuticals, Inc$74
  • Smith+Nephew$71
  • plus $363 from 10 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)134$2,051
Hollister Incorporated4$124
Vertos Medical, Inc.1$92
Amneal Pharmaceuticals LLC4$84
Ipsen Biopharmaceuticals, Inc4$74
Smith+Nephew4$71
Piramal Critical Care3$67
Coloplast4$61
Avanir Pharmaceuticals, Inc.3$53
Merz North America, Inc.1$38
ABC Home Medical Supply, Inc.2$37
Pacira Pharmaceuticals Incorporated1$29
Acadia Pharmaceuticals Inc2$27
Dermira, Inc.1$20
Philips North America LLC1$18
Saol Therapeutics Inc.1$13

How this compares

Too few spinal cord injury medicine providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$149,592
Medicare patients
308
Services billed
1,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dantrolene Sodium100$16,489
MyrbetriqMirabegron27$15,527
LinzessLinaclotide16$9,959
Baclofen307$7,532
Gabapentin520$6,505
Methenamine Hippurate86$3,971
Pregabalin106$3,827
Duloxetine Hcl91$2,306
Midodrine Hcl41$2,171
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$1,967
Venlafaxine Hcl ErVenlafaxine Hcl18$1,666
Tizanidine Hcl71$1,577
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen39$1,391
Cyclobenzaprine Hcl54$895
Lubiprostone12$742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,051$9,95916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few spinal cord injury medicine providers in Kentuckyon file to place this against a meaningful peer group, so we don't.

Other spinal cord injury medicine in Lexington

Where these figures come from

Is this you, or does something look wrong? →